Hanmi Pharm signed an license agreement of new bio-drug with Janssen
Hanmi Pharm(CEO Kwan-soon Lee) announced a license agreement to develop and commercialize HM12525A (LAPSGLP/GCG), a self-developed oxyntomodulin-based diabetes and obesity treatment, with Janssen on the 9th. Janssen is planning to have a phase 2 clinical trial of HM12525A in 2016.
HM12525A, a do...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
